期刊文献+

唑来膦酸治疗前列腺癌骨转移疼痛的疗效观察 被引量:3

原文传递
导出
摘要 目的 探讨唑来膦酸对晚期前列腺癌骨转移疼痛的治疗价值。方法 将60例因骨转移导致骨痛的晚期前列腺癌患者随机分为两组:观察组30例应用唑来膦酸同时最大限度雄激素阻断治疗;对照组30例仅给予最大限度雄激素阻断治疗;分别观察镇痛效果、生活质量及患者不良反应等。结果 疼痛程度两组疗效比较,观察组临床受益率为93.3 %(28/30),对照组临床受益率为76.7 %(23/30),观察组止痛疗效好于对照组;生活质量两组疗效比较,观察组有效率为90.0 %(27/30),对照组有效率为73.3 %(22/30)。但两组疗效差异无统计学意义(P>0.05)。治疗中未发现严重不良反应。结论 唑来膦酸和最大限度雄激素阻断治疗是缓解晚期前列腺癌骨痛的有效手段。
作者 佟倩 黄英
出处 《肿瘤研究与临床》 CAS 2013年第1期56-57,共2页 Cancer Research and Clinic
  • 相关文献

参考文献6

  • 1Parkin DM, Bray F, Ferlay J, et ak Global cancer statistics,2002. CA Cancer J Clin, 2005, 55: 74.
  • 2Guise TA, Mundy GR. Cancer and bone. Endocr Rev, 1998, 19: 18- 54.
  • 3马建辉,王金万.前列腺肿瘤//董志伟,谷铣之.临床肿瘤学.北京:人民卫生出版社,2002:1146.
  • 4周利群,张仲一.双磷酸盐在前列腺癌治疗中的应用[J].中华临床医师杂志(电子版),2009,3(4):6-10. 被引量:3
  • 5Daniell HW, Dunn SR, Ferguson DW, et al. Progessive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 2000, 163: 181-186.
  • 6Croucher P, Jagdev S, Coleman R. The anti-tumor potential of zoledronic acid. Breast, 2003, 12 (Suppl 2): S30-36.

二级参考文献1

  • 1S. Eriksson,A. Eriksson,R. Stege,K. Carlstr?m. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens[J] 1995,Calcified Tissue International(2):97~99

共引文献2

同被引文献34

  • 1古力米热,王军起,张洁祥,邓刚.中国维吾尔族男性CYP17基因多态性与前列腺癌发生的关系[J].中华男科学杂志,2006,12(2):120-122. 被引量:4
  • 2Ramankulov A, Lein M, Kristiansen G, et al.Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer[J].Prostate, 2007,67 ( 3 ) : 330-340.
  • 3Gu Z, Thomas G, Yamashiro J, et al.Prostate stem cell antigen (PSCA)expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer[J].Oncogene, 2000,19 ( 10 ) : 1288-1296.
  • 4Morote J, Morin JP, Ors01a A, et al.Prevalence of osteoporosis during long term androgen deprivation therapy in patients with prostate cancer[J].J Urol, 2007,69 ( 2 ) : 500-505.
  • 5Tralongo P, Repetto L, Marl A, et al.Safety of long-term administration of bisphosphonates in elderly cancer patients[J].Oncology,2004,67 ( 3 ) : 112-116.
  • 6Robertson AG, Reed NS, Ralston SH, et al.Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study[J].Journal of Clinical Oncology, 1995,13 ( 9 ) :, 2427-2430.
  • 7Terpos E, Sezer O, Croucher PI, et al.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network[J].Ann Oncol,2009,20 ( 8 ): 1303-1317.
  • 8American Society of Clinical Oncology.American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer[J].J Clin Oncol, 2011, 29 ( 16 ) : 2293-2296.
  • 9Ferrari-Lacraz S, Ferrari S.Do RANKL inhibitors (denosumab) affect inflammation and immunity?[J]. Osteoporos Int, 2011,22 ( 2 ) : 435-446.
  • 10Tsourdi E, Rachner TD, Rauner M, et al.Denosumab for bone diseases: translating bone biology into targeted therapy[J].Eur J Endocrinol, 2011,165 ( 6 ) : 833-840.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部